Complement in action: An analysis of patent trends from 1976 through 2011

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 301-313

  Yang, Kun ^a   Deangelis, Robert A ^a   Reed, Janet E ^b   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Potter Anderson and Corroon LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5B; COMPLEMENT INHIBITOR;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; CYTOLYSIS; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; IMMUNOASSAY; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; INNATE IMMUNITY; LIPID METABOLISM; MEDICAL RESEARCH; NEOPLASM; NOMENCLATURE; NONHUMAN; ORGAN TRANSPLANTATION; PATENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN TARGETING; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SEPSIS; SIGNAL TRANSDUCTION; TISSUE REGENERATION; TUMOR MICROENVIRONMENT; ADAPTIVE IMMUNITY; AGE RELATED MACULAR DEGENERATION; CLINICAL RESEARCH; COMPLEMENT DISORDER; DIAGNOSIS; DRUG DEVELOPMENT; HOMEOSTASIS; IMMUNOMODULATION; INFECTION; MALIGNANT NEOPLASM; TREND STUDY;

EID: 84934440319     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_21     Document Type: Conference Paper

References (58)

1. Ahearn JM, Manzi SM, Liu C-C (2009) Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells. US Patent 7,585,6400
2. Allikmets RL, Hageman GS, Dean MC, Gold AM (2011) Variants in complement regulatory genes predict age-related macular degeneration. US Patent 8,012,6833
3. Asgari E, Zhou W, Sacks S (2010) Complement in organ transplantation. Curr Opin Organ Transplant 15:486-4911
4. Baas F, Ramaglia V (2010) Complement inhibition for improved nerve regeneration. US Application 201001433444
5. Bell L (2008) Methods for reducing morality associated with acute myocardial infarction. US Patent 7,361,3399
6. Bell L, Rother RP (2009) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of Complement. US Application 200902205088
7. Bing DH (1983) Means and methods for purifying Clq, Clr and Cls. US Patent 4,374,0611
8. Bosmann M, Ward PA (2012) Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 946:147-1599
9. Conrow RB, Bernstein S (1978) 1,3,5- or 1,3,6- naphthalenetriyltris(sulfonylimino)aryl acids and salts. US Patent 4,087,6133
10. Conrow RB, Poletto JF, Bernstein S (1978) 5-Carboxy- phenylenebis(carbonylimino)benzene carboxylic and dicarboxylic acids and salts. US Patent 4,089,9744
11. Day AJ, Clark SJ, Bishop PN, Sim RB, Blom AM, Heinegard D (2010) Screening assays for binding antagonists of the AMD-associated variant of factor H (H384). US Patent 7,829,3011
12. Deschatelets P, Olson P, Francois C (2007) Compstatin and analogs thereof for eye disorders. US Application 200702386544
13. Diamond LE, Logan JS, Byrne GW, Sharma A (2000) Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor. US Patent 6,166,2888
14. Dinu V (2007) Methods of preventing and treating Alzheimer's disease, age-related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system. US Application 200701963677
15. Evans MJ, Matis LA, Mueller EE, Nye SH, Rollins S, Rother RP, Springhorn JP, Squinto SP, Thomas TC, Wilkins JA (2002) C5-specific antibodies for the treatment of inflammatory diseases. US Patent 6,355,2455
16. Francois C, Deschatelets P, Olson P (2011) Compositions and methods for treatment of trauma. US Application 201100924466
17. Francois C, Deschatelets P, Olson P (2011) Viral complement control proteins for eye disorders. US Patent 7,947,2677
18. Fujii S, Yaegashi T, Nakayama T, Sakurai Y, Nunomura S, Okutome T (1986) Amidine compound, process for producing same and anti-complement agent comprising same. US Patent 4,570,0066
19. Fujii S, Nakayama T, Nunomura S, Matsui R, Watanabe S-i, Sudo K, Okutome T, Kurumi M, Sakurai Y, Aoyama T (1987) Novel amidine compound. US Patent 4,634,7833
20. Fung SC, Mollnes TE (2007) Methods and compositions for the prevention and treatment of sepsis. US Application 200702749899
21. Hallgren HR, Wide LE (1980) Method of indicating rheumatoid factors. US Patent 4,184,8477
22. Hass P, Jianping Y, Katschke Jr K, Steffek M, Wiesmann C, Van Lookeren CM (2011) Prevention and treatment of complement-associated eye conditions. US Patent 8,007,7911
23. Heinrich H-W, Hahn H-J, Meyer U, Kruschke P, Wagner H-J (2005) Immunoadsorber for use in sepsis therapy. US Patent 6,881,4088
24. Holers VM (2003) The complement system as a therapeutic target in autoimmunity. Clin Immunol 107:140-1511
25. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal N, Thomsen AC, Garred P (1997) Acquired C3 Deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 40:544-5499
26. Hughes PD, Cohney SJ (2011) Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr Opin Organ Transplant 16:425-4333
27. Jackowski G, Marshall J (2006) Complement C3 precursor biopolymer markers predictive of type II diabetes. US Patent 7,097,9899
28. Lambris JD, Katragadda M (2011) Potent compstatin analogs. US Patent 7,888,3233
29. Lambris JD, Ritis K (2011) Method of treating acute respiratory distress syndrome. US Application 201101428377
30. Lambris JD, Sahu AK (2001) Peptides which inhibit complement activation. US Patent 6,319,8977
31. Lewis AJ, Bernstein S (1981) C6-Modi fied cyclodextrin sulfate salts as complement inhibitors. US Patent 4,258,1800
32. Markiewski MM, Lambris JD (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171:715-7277
33. Markiewski MM, Lambris JD (2009) Unwelcome complement. Cancer Res 69:6367-63700
34. Markiewski MM, DeAngelis RA, Lambris JD (2008a) Complexity of complement activation in sepsis. J Cell Mol Med 12:2245-22544
35. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008b) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225-12355
36. Mullard A (2012) 2011 FDA drug approvals. Nat Rev Drug Discov 11:91-944
37. O'connell JP, Hoke RA, Mize PD (1987) Immunoassay using complement. US Patent 4,693,9700
38. Pettigrew HD, Teuber SS, Gershwin ME (2009) Clinical significance of complement de ficiencies. Ann N Y Acad Sci 1173:108-1233
39. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement Deficiency, and apoptosis. Adv Immunol 76:227-3244
40. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD (2011) Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 48:481-4899
41. Racila EV, Weiner GJ (2007) Assessing response to anti-CD20 therapy by genotyping C1q components. US Patent 7,723,0366
42. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265-12755
43. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785-7977
44. Rosengard AM, Ahearn Jr JM, San fi lippo AP, Baldwin WM III (2000) Use of chimeric vaccinia virus complement control proteins to inhibit complement. US Patent 6,140,4722
45. Rother RP, Wang H, Zhong Z (2010) Prolongation of survival of an allograft by inhibiting complement activity. US Application 201001359922
46. Shafren DR (2008) Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses. US Patent 7,361,3544
47. Sims PJ, Bothwell ALM (1996) Cells expressing high levels of CD59. US Patent 5,573,9400
48. Skattum L, van Deuren M, van der Poll T, Truedsson L (2011) Complement Deficiency states and associated infections. Mol Immunol 48:1643-16555
49. Smith RA, Dodd I, Mossakowkska DEI (2010) Conjugates of soluble peptidic compounds with membrane-binding agents. US Patent 76556177
50. Smith RAG, Pratt JR, Sacks SH (2011) Method of preparing an organ by perfusion. US Patent 7,888,3188
51. Taguchi F, Mitsui I, Hara K, Hayashi M, Ezawa K, Fukunaga K, Kuranari J (1991) Test method involving substanceconjugated complement component C1q. US Patent 5,035,9955
52. Taylor RP, Nardin A, Sutherland WM, Sokoloff MH, Chung L (2003) Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies. US Patent 6,572,8566
53. Thakkinstian A, McKay GJ, McEvoy M, Chakravarthy U, Chakrabarti S, Silvestri G, Kaur I, Li X, Attia J (2011) Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol 173:1365-13799
54. Wang Y, Matis L (2007) Methods for the treatment of inflammatory joint disease. US Patent 7,279,1588
55. Woolf C, Costigan M, Grif fi n R (2006) Methods for treatment of pain. US Application 200602410744
56. Yehoshua Z, Garcia Filho CAA, Gregori G, Li Y, Feuer WJ, Penha FM, Sadda SR, Zhang L, Zhang K, Rosenfeld PJ (2012) Systemic complement inhibition with eculizumab for the treatment of geographic atrophy in AMD patients: the complete study. In: The 2012 ARVO annual meeting
57. Zhu A (2007) Modi fied organs and cells for xenotransplantation. US Patent 7,166,2788
58. Zipfel PF, Lauer N, Skerka C (2010) The role of complement in AMD. Adv Exp Med Biol 703:9-244